TCR2 Therapeutics, Inc.
(NASDAQ : TCRR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 1.10%162.160.7%$1254.93m
PFEPfizer Inc. 2.47%38.530.9%$1060.23m
MRKMerck & Co., Inc. 1.03%77.450.7%$958.24m
ABBVAbbVie, Inc. 1.02%107.981.9%$778.70m
BMYBristol-Myers Squibb Co. 1.54%65.431.0%$758.06m
LLYEli Lilly & Co. 1.76%189.201.1%$575.67m
AZNAstraZeneca Plc -0.18%50.741.2%$463.76m
GSKGlaxoSmithKline Plc 0.21%37.770.2%$217.86m
NVSNovartis AG 0.95%88.030.2%$157.01m
RPRXRoyalty Pharma Plc 0.53%41.870.2%$143.72m
VTRSViatris, Inc. 0.90%13.400.0%$127.48m
CVACCureVac NV 5.04%109.290.0%$96.11m
RGENRepligen Corp. -0.13%213.306.8%$86.07m
NVONovo Nordisk A/S 0.95%72.190.1%$62.10m
SNYSanofi 1.20%51.300.2%$61.19m

Company Profile

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It also involves in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle in May 2015 and is headquartered in Cambridge, MA.